NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
79.02 +0.02 (+0.03%) GOLD FUTURES
2,311.10 +0.10 (+0.00%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,016.87 +1,292.83 (+2.83%)
AMGN May 2024 310.000 put
| Previous close | 46.13 |
| Open | 46.13 |
| Bid | 32.95 |
| Ask | 35.95 |
| Strike | 310.00 |
| Expiry date | 2024-05-17 |
| Day's range | 46.13 - 46.13 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
Investor's Business DailyAmgen Beats First-Quarter Expectations, But Shares Slide As Investors Watch Obesity Space
Amgen stock dipped late Thursday despite beating first-quarter expectations. The company is running a midstage study of its obesity drug.
ReutersAmgen first-quarter profit dips 1%, revenue rises 22%
(Reuters) -Amgen reported a slightly lower first-quarter profit on Thursday, citing higher operating and interest expense from its recent acquisition of rare disease drugmaker Horizon Therapeutics, partially offset by double-digit revenue growth. The biotechnology company's adjusted profit fell 1% to $3.96 per share, which still beat the average analyst estimate of $3.88 per share, according to LSEG data. The results were "essentially in-linish ... although not anything significant for the Street given that it is still early in the year," David Song, portfolio manager of the Tema Obesity & Cardiometabolic ETF said in an email.
PR NewswireAMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
Amgen (NASDAQ:AMGN) today announced financial results for the first quarter 2024.
